What is Lamotrigine?
Lamotrigine is a broad-spectrum antiepileptic drug (AED) that works by blocking voltage-sensitive sodium channels, which inhibits the release of excitatory neurotransmitters, particularly glutamate 1, 2.
Mechanism and Pharmacology
Lamotrigine suppresses seizures through its action on sodium channels, leading to reduced neurotransmitter release. This mechanism gives it activity across a wide range of seizure types, with potency and duration generally superior to many older AEDs 1.
Clinical Indications
Epilepsy Treatment
Lamotrigine is established as effective for refractory partial seizures as add-on therapy, with responder rates (≥50% seizure reduction) ranging from 20-34% in controlled trials 3. The drug demonstrates particular efficacy for:
- Partial seizures with or without secondary generalization - Three class I studies demonstrated responder rates of 20-34% at doses of 300-500 mg/day 3
- Secondarily generalized tonic-clonic seizures - These respond especially well to lamotrigine 2
- Idiopathic generalized epilepsy including absence seizures 1
- Lennox-Gastaut syndrome 1, 2
- Pediatric epilepsies including tuberous sclerosis, juvenile neuronal lipofuscinosis, and Rett syndrome 4
For monotherapy, lamotrigine demonstrated superiority over low-dose valproate, with 56% of evaluable patients completing the study versus 20% on valproate, though only 37% completed in intent-to-treat analysis 3.
Bipolar Disorder
Lamotrigine is effective as add-on treatment during acute depressive episodes in bipolar disorder (SMD -0.30, p = 0.004) and as maintenance treatment for preventing relapse/recurrence (RR 0.84, p = 0.037) 5. It shows mood-stabilizing properties and may improve quality of life 4.
Dosing and Formulations
Lamotrigine is available as extended-release tablets in 25,50,100,200,250, and 300 mg strengths 6.
Critical dosing considerations based on comedications:
- With enzyme-inducing AEDs alone: Standard dosing (300-500 mg/day for epilepsy) 3
- With valproate: Reduce lamotrigine dose by 50% due to pharmacokinetic interactions 3, 7
- With enzyme inducers: Double the standard monotherapy dose 7
Plasma levels are significantly affected by comedications: monotherapy averages 8.7 mg/L, with enzyme inducers 4.8 mg/L, and with valproate 8.7 mg/L 7.
Adverse Effects Profile
The most common CNS side effects are dose-dependent: dizziness, ataxia, nausea, tremor, and diplopia 3, 4. Discontinuation rates due to adverse events range from 5-14% depending on dose 3.
Rash is the most concerning adverse effect, occurring in 10-17% of patients in controlled trials 3. The incidence of severe rash (including Stevens-Johnson syndrome) has decreased markedly since implementation of slower titration guidelines 4. The original study in 3 used faster titration than currently recommended and reported one case of Stevens-Johnson syndrome.
Positive attributes distinguishing lamotrigine from older AEDs:
- No weight gain 4
- No cognitive impairment; may actually improve memory and language function 4
- Mood-stabilizing effects 4
- Likely no teratogenic properties based on newer data 4
Long-Term Outcomes
In real-world clinical practice, retention rates at 1,2,3, and 4 years are 74.4%, 69.3%, 63.1%, and 55.6% respectively 7. The main reason for discontinuation is lack of efficacy (19.1%), with only 1.4% discontinuing due to adverse events 7. However, only 1.4% of patients achieved complete seizure freedom over 48 months of follow-up 7.
Special Populations
In children, lamotrigine is considered by some epileptologists as a drug of first choice in older school children and adolescents due to its favorable tolerability profile 4. It can be used effectively in children under 2 years of age, though dosing requires careful attention to comedications 8.
During pregnancy, lamotrigine clearance increases substantially in 75% of women, requiring dose adjustments and therapeutic drug monitoring to prevent breakthrough seizures 9.